This video demonstrates how the VIA Thaw CB1000 can standardize a critical step in the delivery of cell therapies with a simple, reproducible and traceable process for recovering cryopreserved samples in cryobags.
A video introduction on the VIA Freeze™ range which are liquid nitrogen-free controlled-rate freezers to cryopreserve any type of samples.
An overview of the regulatory requirements given in the latest guidance documents as well as a description of new technologies for determining the identity of cell substrates and virus seed stocks and detecting adventitious agent contamination.
Rapid growth and geographic expansion in the biopharmaceutical market is increasing supply chain risks that need to be well understood.
Learn more about how free trade zones can offer cost-efficient ways to manage your clinical trial.
See how this service can benefit you with shorter lead time, less waste, less stock out risk and no booklet labels.
CSafe Global announces a significant strategic growth milestone with the manufacture of the 1000th RKN active container. This accomplishment is a testament to the dedication of our manufacturing, customer service, technical support and sales team as we continue to meet the increasing demand from biopharmaceutical companies for the CSafe RKN.
Get the performance, Peace of Mind®, and cost savings you’ve been looking for with CSafe’s AcuTemp® brand passive packaging. Our passive solutions are engineered around the superior thermal attributes of CSafe’s ThermoCor® VIP and are designed and tested to maintain specific temperature range and duration. The passive solutions assortment includes packaging for 2-8°C, CRT and frozen with hold times up to 240 hours and payload volumes up to 50 liters.
Biopharma product shipments can save and improve lives and have positive impacts on entire communities - but only if they arrive safe, stable, and effective.
At the most recent eyefortransport Life Sciences conference, SupplyChainBrain asked Dave Bode, DSC's Vice President, Health Care Solutions, to describe the difference between what kind of supply chain partner life science companies need now to accomplish their business goals and what used to be sufficient.
|
|
|
|
|
|
|
|
|